- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.01. | Rodman & Renshaw initiates Telomir Pharma stock with Buy rating | 1 | Investing.com | ||
| 05.01. | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models | 259 | ACCESS Newswire | In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity on both tumor growth and cancer cell spread. MIAMI, FLORIDA / ACCESS Newswire... ► Artikel lesen | |
| 05.01. | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 22.12.25 | Telomir Pharmaceuticals beschließt neues Vergütungspaket für CEO | 3 | Investing.com Deutsch | ||
| 18.12.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development | 290 | ACCESS Newswire | No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir... ► Artikel lesen | |
| 17.12.25 | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 26.11.25 | RECIPHARM AB: Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support | 2 | Cision News | ||
| TELOMIR PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 25.11.25 | Telomir reports PSA reduction in prostate cancer cells with lead drug | 2 | Investing.com | ||
| 25.11.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells | 273 | ACCESS Newswire | PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November... ► Artikel lesen | |
| 21.11.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells | 355 | ACCESS Newswire | Findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. MIAMI, FL... ► Artikel lesen | |
| 20.11.25 | Craig Eagle verlässt Aufsichtsrat von Telomir Pharmaceuticals | 1 | Investing.com Deutsch | ||
| 20.11.25 | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine in Reducing Intracellular Iron in a Human Cell Line | 355 | ACCESS Newswire | New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulating... ► Artikel lesen | |
| 12.11.25 | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 10.11.25 | Telomir Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 23.10.25 | Telomir-1 shows promise in modulating cancer defense genes | 13 | Investing.com | ||
| 23.10.25 | Telomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's "Kill-and-Clean" Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo | 290 | ACCESS Newswire | New findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ACCESS... ► Artikel lesen | |
| 22.10.25 | Telomir Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.10.25 | Telomir to Buy TELI | 2 | Baystreet.ca | ||
| 21.10.25 | Telomir Pharmaceuticals executes LOI for worldwide rights to Telomir-1 | 3 | Seeking Alpha |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 99,80 | +0,60 % | Weiteres Potenzial für BIONTECH | Nach der Fusion mit Curevac steigt der Zielumsatz für 2026/2027 auf 3,7 bis 3,9 Mrd. €. Auch 4 Mrd. € sind im Zuge der verschiedenen Kooperationen mit englischen und amerikanischen Partnern denkbar.... ► Artikel lesen | |
| MODERNA | 40,750 | +0,90 % | Opening Bell: Intel, Micron Technology, Lockheed Martin, Alibaba, Moderna, Lynas, Netflix | Die US-Börsen haben am Mittwoch kräftig zugelegt. Der Dow Jones stieg 1,21 Prozent, der Nasdaq Composite gewann 1,18 Prozent hinzu. Kurstreiber war ein politisches Signal: US-Präsident Donald Trump... ► Artikel lesen | |
| VALNEVA | 3,948 | -0,20 % | Valneva zieht US-Zulassungsanträge für IXCHIQ zurück - Aktie unter Druck | Die Valneva SE hat die Zulassungsanträge (BLA und IND) für ihren Chikungunya-Impfstoff IXCHIQ in den USA freiwillig zurückgezogen. Hintergrund sind regulatorische Maßnahmen der U.S. Food and Drug Administration... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,280 | +0,79 % | INOVIO Pharmaceuticals, Inc.: FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) | PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help... ► Artikel lesen | |
| OCUGEN | 1,376 | +2,42 % | Ocugen closes $22.5 million registered direct offering | ||
| VIKING THERAPEUTICS | 26,505 | -0,77 % | Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? | ||
| BAVARIAN NORDIC | 26,540 | +1,03 % | Bavarian Nordic A/S: Bavarian Nordic Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil | Agreement to enable the first entry in Latin America for Bavarian Nordic's chikungunya vaccinePotential to expand agreement to cover rest of Latin America
COPENHAGEN, Denmark, January 23, 2026 -... ► Artikel lesen | |
| GERON | 1,153 | +0,30 % | Geron Corporation Provides 2026 Financial Guidance | 2026 RYTELO (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and... ► Artikel lesen | |
| IMMUNITYBIO | 5,092 | -2,49 % | ImmunityBio-Aktie: Jetzt noch mit der Kursrakete mitfliegen? | Die ImmunityBio-Aktie machte einen Raketenstart ins neue Jahr. Bis gestern schoss der Kurs des Biotech-Unternehmens von 2,00 auf 5,50 US$ hoch. Doch am Dienstagmorgen bricht der Biotech-Titel im europäischen... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 2,370 | -2,39 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | 26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif.... ► Artikel lesen | |
| ZAI LAB LTD ADR | 15,000 | +0,67 % | Zai Lab's Augtyro receives NMPA approval for solid tumours in China | ||
| VERASTEM | 5,150 | -1,90 % | Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma | GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 18,360 | -0,81 % | Apellis Valuation Ignores Empaveli Potential, Says Analyst | ||
| ADMA BIOLOGICS | 16,960 | +1,37 % | ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? | ||
| ANNOVIS BIO | 2,525 | +2,43 % | Annovis Bio Inc.: Annovis Announces Novel Biomarker Data in Alzheimer's Patients Supporting Buntanetap's Potential as a Disease-Modifying Treatment | MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen |
Das Unternehmen TELOMIR PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,320 Euro und damit -1,49 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TELOMIR PHARMACEUTICALS INC finden Sie auf Wallstreet Online.